Search 

Medtronic was founded in 1949 and is based in Minneapolis Minnesota. Medtronic makes strategic investments and acquisitions in the medical device sector and is focused on cardiovascular diseases diabetes diseases of the nervous system (including Parkinson's disease and dystonia) and musculoskeletal conditions. The firm has acquired a number of medical technology and biotechnology companies. Medtronic is also interested in orthopedic products sports health products and telehealth/connected medical devices (particularly consumer apps for health management). Medtronic also makes grants to non-profit organizations. Instructions on applying for investment or grants can be found at Innovate With Medtronic: http://www.medtronic.com/innovation/innovate-with-medtronic.html

Mesa Verde Venture Partners is a Venture Capital company founded in 2006. The firm is currently making investments out of its 2nd fund that had its first close in 2013. The firm makes primarily equity investment into seed and early stage rounds ranging from $500,000 to $1 million initially and up to $1.5 million over the lifetime of the investment. The firm is focused on companies located in the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

Mid Atlantic Bio Angels (MABA) founded in 212 is an angel investor group based in the New York City area which focuses exclusively on new and emerging life science companies. The group places no geographical restrictions or requirements for presenting companies as long as meaningful and effective post-investment monitoring of these companies can be achieved, MABA has considered opportunities in Europe and Israel as well as across the USA and Canada. Since the members are investing their own capital the investment size is highly flexible and will depend on the financial needs of the company. The capital structure is typically in preferred stocks or convertible notes in qualified cases. The group prefers to invest in companies with valuations of less than $5M. As MABA prefers opportunities that can be entirely angel-financed MABA generally requires that companies can achieve exit with $15 million capital or under (generally after raising a Series B round but no further rounds).

The Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute supports the development of innovative biomedical products to address unmet medical needs in the heart, lung, blood and sleep fields.  OTAC is home to the NHLBI's small business programs (SBIR and STTR) and the NIH Centers for Accelerated Innovations.

The NHLBI's SBIR and STTR programs comprise one of the largest sources of early-stage capital for U.S. small business, acting as engines of innovation for developing and commercializing novel technologies and products that aid in the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding opportunities and resources to support small businesses performing research and development on technologies related to the mission of NHLBI. With an annual budget of $85M, the NHLBI funds about 200 companies each year through the Institute's small business programs.

The NIH Centers for Accelerated Innovations accelerate translation of scientific discovery into commercial products that improve health for patients. This unique public-private partnership is changing the way discoveries with scientific and commercial potential are identified and developed.

Norfolk Medical pioneered the oncology market in 1981 by developing one of the first vascular access ports for long-term access.  Since then, we have continued to develop innovative cutting-edge medical devices.  Our latest development is a device for diabetes that allows the body to be insulin independent.  Our device is the world's first active immunoisolation device that facilitates the exchange of oxygen, nutrients, and waste products while protecting against the bodies immune response without the use of additional drugs or immunosuppressant’s.  We are confident that the basic principles of the device can be applied to other applications from anemia and liver failure (NASH) to ALS.  We are currently in the pre-clinical stage of research and are actively looking for a strategic partner to develop this product. 

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).